Evidence map›Paper›PMID 39076022›Full record

ArticleBiotechnology progress

Tangential flow filtration-facilitated purification of human red blood cell membrane fragments and its preferential use in removing unencapsulated material from resealed red blood cell ghosts compared to centrifugation.

Xiangming Gu, Andre F Palmer

Abstract readComparative Study
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiangming GuWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0001-9096-5911
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.

Funding

PEGylated megahemoglobin for use as a red blood cell substituteR01HL138116 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, KAUMAYA, PRAVIN T. P. · 2017 to 2020
$2.9M
Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseasesR01HL158076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUEHLER, PAUL WERNER, IRWIN, DAVID CHARLES · 2022 to 2025
$2.5M
Engineering a novel biomaterial for oxygen transport applicationsR01HL156526 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, PALMER, ANDRE FRANCIS · 2021 to 2024
$2.5M
Attenuating the Oxidative and Myocardial Side-Effects of Acellular HemoglobinR01HL126945 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.7M
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic BioreactorsR01EB021926 · NIBIB · OHIO STATE UNIVERSITY · PI BERTHIAUME, FRANCOIS, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.4M
NHLBI NIH HHS R01 HL126945NHLBI NIH HHS R01 HL138116NHLBI NIH HHS R01 HL156526NHLBI NIH HHS R01 HL158076NHLBI NIH HHS R01 HL159862NHLBI NIH HHS R01 HL162120NIBIB NIH HHS R01 EB021926NIH HHS R01EB021926NIH HHS R01HL126945NIH HHS R01HL138116NIH HHS R01HL156526NIH HHS R01HL158076NIH HHS R01HL159862NIH HHS R01HL162120U.S. Department of Defense W81XWH-18-1-0059
6 · The paper itself

Abstract

The biodistribution of many therapeutics is controlled by the immune system. In addition, some molecules are cytotoxic when not encapsulated inside of larger cellular structures, such as hemoglobin (Hb) encapsulation inside of red blood cells (RBCs). To counter immune system recognition and cytotoxicity, drug delivery systems based on red blood cell membrane fragments (RBCMFs) have been proposed as a strategy for creating immunoprivileged therapeutics. However, the use of RBCMFs for drug delivery applications requires purification of RBCMFs at large scale from lysed RBCs free of their intracellular components. In this study, we were able to successfully use tangential flow filtration (TFF) to remove >99% of cell-free Hb from lysed RBCs at high concentrations (30%-40% v/v), producing RBCMFs that were 2.68 ± 0.17 μm in diameter. We were also able to characterize the RBCMFs more thoroughly than prior work, including measurement of particle zeta potential, along with individual TFF diacycle data on the cell-free Hb concentration in solution and time per diacycle, as well as concentration and size of the RBCMFs. In addition to purifying RBCMFs from lysed RBCs, we utilized a hypertonic solution to reseal purified RBCMFs encapsulating a model protein (Hb) to yield resealed Hb-encapsulated RBC ghosts (Hb-RBCGs). TFF was then compared against centrifugation as an alternative method for removing unencapsulated Hb from Hb-RBCGs, and the effects that each washing method on the resulting Hb-RBCG biophysical properties was assessed.

Indexed as

CentrifugationErythrocyte MembraneErythrocytesFiltrationDrug Delivery SystemsHemoglobinsHumansHemoglobinshemoglobin removalred blood cellred blood cell ghostred blood cell membrane fragmenttangential flow filtration

Identifiers

PMID39076022
PMCPMC11659797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.